You are here: Industry Insights > Pfizer

News List

Allergan sues Pfizer, saying it needs to cover its opioid liabilities for Kadian fiercepharma
August 06, 2018
Like a game of hot potato, painkiller Kadium has been passed around a group of pharma players in the last decade, from Alpharma to King Pharma, to Actavis and Allergan.
Pfizer halts sales of injectable opioids to veterinarians as shortages persist fiercepharma
August 03, 2018
Dogs, cats and other animals are now feeling the pain of Pfizer’s manufacturing problems that have contributed to a nationwide shortage of injectable opioids. The drugmaker has halted sales of the painkillers to veterinarians until sometime next year.
Pfizer unveils its first oncology biosimilar in Europe pharmaceutical-technology
August 03, 2018
The European Commission (EC) has approved trazimera (trastuzumab), Pfizer’s biosimilar to Roche’s Herceptin, making it Pfizer’s first oncology biosimilar to be approved in Europe.
Pfizer notches two EU approvals, including Herceptin biosimilar pharmafile
August 02, 2018
Pfizer is patting itself on the back after securing two new approvals in Europe within 24 hours: Xeljanz (tofacitinib citrate) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients for whom other therapies have prove
Pfizer CEO psychs up investors for a rebate-free world under Trump fiercepharma
August 02, 2018
What would a world with no drug rebates look like? Pfizer’s Ian Read is already imagining it.
EC approves Pfizer's Herceptin biosimilar pharmatimes
August 02, 2018
Pfizer's Herceptin (trastuzumab) biosimlar Trazimera has been approved by the European Comission.
Pfizer receives EU nod for Ulcerative Colitis drug XELJANZ biospectrumasia
August 02, 2018
XELJANZ is the first and only oral therapy and Janus kinase (JAK) inhibitor to be approved for this patient population
Biosimilars and key brands drive Pfizer to raise forecasts pharmatimes
August 02, 2018
Pfizer’s second-quarter sales have beat estimates, thanks to strong sales of Eliquis, Ibrance and Xeljanz.
Pfizer's Xeljanz cleared for ulcerative colitis in Europe pharmatimes
August 02, 2018
The European Commission has approved Pfizer’s Xeljanz (tofacitinib citrate) for ulcerative colitis (UC), making it the first oral therapy and Janus kinase (JAK) inhibitor to be approved for this patient population.
A slowing market—not new rivals—is hurting Pfizer's star cancer drug Ibrance, executives say pfizer
August 02, 2018
Pfizer breast-cancer fighter Ibrance posted a rare sales miss Tuesday, but it wasn't because new rivals are stealing its share.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page